Indian Journal of Animal Research

Indian Journal of Animal Research cover
Volume 60 · Issue 6 · 2025/06/17

Therapeutic Evaluation of Sacubitril-valsartan (Arni) in Canine Dilated Cardiomyopathy

K.S. Saikrishna
K. Jeyaraja
P. Selvaraj
S. Vairamuthu
Md. Shafiuzama
562 Views

Submitted

2025/03/22

First Online

2025/06/17

doi

10.18805/IJAR.B-5588

Cite article - K.S. Saikrishna, K. Jeyaraja, P. Selvaraj, S. Vairamuthu, Md. Shafiuzama. (2025). Therapeutic Evaluation of Sacubitril-valsartan (Arni) in Canine Dilated Cardiomyopathy. Indian Journal of Animal Research. 60(6): 1021–1029. doi: 10.18805/IJAR.B-5588

Abstract

Background: Canine dilated cardiomyopathy (DCM) is one of the commonly diagnosed acquired myocardial disease in dogs characterized by hypokinesis, eccentric myocardial hypertrophy. Activation of neurohumoral system ( i.e. , sympathetic and RAAS) is crucial in the pathogenesis of DCM with deteriorative effect on the failing heart. In current protocol, ACE inhibitors are being employed to counter RAAS through blocking of ACE pathway, however aldosterone breakthrough due to alternate tissue pathway render the treatment less effective. The natriuretic peptides ( viz ., ANP, BNP) produced in response to cardiac wall stress have beneficial natriuretic, diuretic and suppressed cardiac sympathetic effects, however, will be cleaved by the enzyme neprilysin limiting their activity. With this background, this study was aimed to study the effect of Sacubitril-Valsartan, an ARNi drug in management of canine heart failure due to DCM, evaluating its effects on clinical, echocardiographic parameters as well as on RAAS and natriuretic peptides.

Methods: Dogs with confirmed DCM on echocardiography were randomly divided into two treatment groups, one with conventional protocol having ACEI (Group II) and another group with ARNi replacing ACEI in the protocol (Group III). Clinical signs, ECG, echocardiographic evaluation was done at monthly interval till 90 th day of therapy. Radiographic evaluation as well as effect on RAAS by assessing plasma natriuretic peptides and urine aldosterone-creatinine ratio was done on 0 th day and 90 th days of therapy. Data was analysed using ANOVA and independent ‘t’ test followed by LSD using IBM SPSS version 2.0.

Result: In the study, group III dogs showed early resolution of clinical signs compared to group II. Group III showed a significant decrease in left atrial diameter and LA/Ao ratio earlier by 30 th day of therapy, while in Group II, the same was noticed on the 60 th day. Cardiac internal diameters were found to be significantly decreased in group III while group II showed a non-significant decrease. Systolic function was found to be significantly increased by 30 th day in group III while group III has a non significant increase in ejection fraction. Significant decline of Uald:cre ratio was noticed in group III indicating its effective inhibition of RAAS. In the study dogs treated with sacubitril-valsartan was found to have faster resolution of clinical signs, greater reduction in cardiac dimensions and improvement in systolic function compared to ACEI treated dogs.

References

  1. Ames, M.K., Atkins, C.E., Eriksson, A. and Hess, A.M. (2017). Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease. J. Vet. Cardiol . 19(3): 218-227. Bolla, G.B., Fedele, A., Faggiano, A., Sala, C., Santangelo, G. and Carugo, S. (2022). Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction. BMC Cardiovascular Disorders . 22(1): 1-8. Boon, J.A., (2011). Veterinary Echocardiography. Second edition. John Wiley and Sons. United Kingdom. Borgarelli, M., Tarducci, A., Tidholm, A. and Haggstrom, J. (2001). Canine idiopathic dilated cardiomyopathy. Part II: pathophysiology and therapy. Vet. J . 162(3): 182-195. Braunwald, E. (2015). The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure. J. Am. Coll. Cardiol . 65(10): 1029-1041. Buchanan, J.W. and Bucheler, J. (1995). Vertebral scale system to measure canine heart size in radiographs. J. Am. Vet. Med. Assoc . 206: 194-194. Cunningham, S.M., Rush, J.E. and Freeman, L.M. (2012). Systemic inflammation and endothelial dysfunction in dogs with congestive heart failure. J. Vet. Intern. Med . 26(3): 547-557. D’ Elia, E., Iacovoni, A., Vaduganathan, M., Lorini, F.L, Perlini, S. and Senni, M. (2017). Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. Eur. J. Heart Fail . 19(6): 710-717. Di Raimondo, D., Tuttolomondo, A., Butta, C., Miceli, S., Licata, G. and Pinto, A. (2012). Effects of ACE-inhibitors and angiotensin receptor blockers on inflammation. Curr. Pharm. Des . 18(28): 4385-4413. Domanjko Petriè, A., Lukman, T., Verk, T.B. and Nemec, S.A. (2018). Systemic inflammation in dogs with advanced-stage heart failure. Acta Vet. Scand . 60(1): 1-9. Dutton, E. and López Alvarez. J. (2018). An update on canine cardiomyo-pathies-is it all in the genes?. J. Small Anim Pract . 59(8): 455-464. Ettinger, S.J., Feldman. E.C. and Cote, E. (2017). Textbook of Veterinary Internal Medicine-Inkling E-Book. 8 th Edn.Elsevier health Sciences. pp. 2868-2869 Gasparini, S., Fonfara, S., Kitz, S., Hetzel, U. and Kipar, A. (2020). Canine dilated cardiomyopathy: Diffuse remodeling, focal lesions and the involvement of macrophages and new vessel formation. Veterinary pathology . 57(3): 397-408. Goncalves, A.V., Pereira-da-Silva, T., Galrinho, A., Rio, P., Branco, L.M., Soares, R., Moreira, R.I. and Ferreira, R.C. (2020). C-reactive protein reduction with sacubitril-valsartan treatment in heart failure patients. Am. J. Cardiovasc. Dis . 10(3): 174-181. Harmon, M.W., Leach, S.B. and Lamb, K.E. (2017). Dilated cardiomyopathy in standard schnauzers: retrospective study of 15 cases. J. Am. Anim. Hosp. Assoc . 53(1): 38-44. Janus, I., Noszczyk-Nowak, A., Nowak, M., Ciaputa, R., Kandefer- Gola, M. and PasIawska, U. (2016). A comparison of the histopathologic pattern of the left atrium in canine dilated cardiomyopathy and chronic mitral valve disease. BMC Vet. Res . 12(1): 1-7. Jeyaraja, K., Arun, A., Hamsa, Y.S., Sesh, P.S.L. and Nambi, A.P. (2015). Diagnostic evaluation of dilated cardiomyopathy in Labrador Retrievers. Int. J. Adv. Res . 3(12): 628-655. Kumar, A., Dey, S., Saxena, A.C. and Mahajan, S. (2018). Evaluation of add on effect of carvedilol on standard protocol of digoxin, frusemide and benazepril in the management of dilated cardiomyopathy in dogs. Indian Journal of Animal Research . 52(4): 583-590. doi: 10.18805/ijar.B-3377 . Kuwahara, K. (2021). The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications. Pharmacology and Therapeutics . 227: 107863. Lantis, A.C., Ames, M.K., Atkins, C.E., DeFrancesco, T.C., Keene, B.W. and Were, S.R. (2015). Aldosterone breakthrough with benazepril in furosemide activated renin angiotensin aldosterone system in normal dogs. J. Vet. Pharmacol. Ther . 38(1): 65-73. Larouche Lebel, E., Loughran, K.A., Huh, T. and Oyama, M.A. (2021). Effect of angiotensin receptor blockers and angiotensin converting enzyme 2 on plasma equilibrium angiotensin peptide concentrations in dogs with heart disease. J. Vet. Intern. Med . 35(1): 22-32. Lee, N.S. and Daniels, L.B. (2016). Current understanding of the compensatory actions of cardiac natriuretic peptides in cardiac failure: A clinical perspective. Card. Fail. Rev . 2(1): 14. McMurray, J.J., Packer, M., Desai, A.S., Gong, J., Lefkowitz, M.P., Rizkala, A.R. and Zile, M.R. (2014). Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl J. Med . 371: 993-1004. Mochel, J. (2019). A review of relevant therapeutic targets for the management of congestive heart failure in dogs: Present and future directions. Preprints . pp. 2019030082. Newhard, D.K., Jung, S., Winter, R.L. and Duran, S.H. (2018). A prospective, randomized, double blind, placebo controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease. J. Vet. Intern. Med . 32(5): 1555-1563. Saini, N., Uppal, S.K. and Anand, A. (2021). Radiographic assessment of dogs with congestive heart failure. Indian Journal of Animal Research . 57(7): 922-927. doi: 10.18805/IJAR.B-4352 . Sun, Y., Song, S., Zhang, Y., Mo, W., Zhang, X., Wang, N., Xia, Y., Tse, G. and Liu,Y. (2022). Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure. ESC Heart Fail . 9(1): 667-675. Volpe, M. (2014). Natriuretic peptides and cardio-renal disease. Int. J. Cardiol . 176(3): 630-639. Webb, R.L. and de Gasparo, M. (2001). Role of the angiotensin II receptor blocker valsartan in heart failure. Exp. Clin. Cardiol . 6(4): 215. Yadav, A., Kumar, T., Sindhu, N., Agnihotri, D., Jajoria, C. and Sharma, M. (2023). Characterization of cardiac diseases in dogs prevalent in Indian Conditions. Indian Journal of Animal Research . 57(5): 644-649. doi: 10.18805/IJAR.B-4544 .
EDITORIAL BOARD

Guided by Experienced Academic Leadership

Distinguished scholars and subject experts committed to editorial excellence, scientific integrity and rigorous peer review.

View Full Board
Yashpal Singh Malik
Chief Editor

Yashpal Singh Malik

Deputy Director General (Agricultural Education)Indian Council of Agricultural Research, Headquarters, New Delhi , India

L.D. Singla
Associate chief editor

L.D. Singla

Professor and HeadAbhilashi University, Chachyot, Himachal Pradesh, India

Vilas G. Atkare
Editor

Vilas G. Atkare

DeanDr. Panjabrao Deshmukh Krishi Vidyapeeth, Akola, Krishi Nagar, Maharashtra, India

S. Maya
Editor

S. Maya

Associate Dean and Professor & HeadKerala Veterinary and Animal Sciences University, Mannuthy, Thrissur, Kerala, India